Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
HHKEX:6990447.80
HKD
-25.40
(-5.37%)
ISIN
CNE1000062J1
Return %
Stock
S&P 500
1Y
-1.24
14.20
3Y
517.23
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jun You Ge
- Full Time Employees
- 2,045
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 666 Xinhua Avenue Chengdu SI China 611100
- IPO Date
- Jul 11, 2023
- Website
- kelun-biotech.com
- Similar Companies
- Business
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) engages in the research, development, manufacturing and commercialization of innovative biopharmaceutical products with a focus on oncology, immunology and related therapeutic areas. Kelun-Biotech operates through integrated in-house capabilities spanning discovery, preclinical and clinical development, process development, manufacturing, quality control, and global registration activities, aiming to bring ADCs and other biologics to domestic and international markets. The company maintains an extensive product pipeline centered on antibody-drug conjugates and other targeted therapies, with SKB264 and A166 as leading candidates in development for various solid tumors, including TNBC, RM-NPC, HER2+ breast cancer, and other oncology indications. Its core products and services include early-stage discovery programs, translational research, clinical trial management, large-scale cGMP manufacturing, fill-finish operations, regulatory submissions and interactions, pharmacovigilance, and commercialization support across multiple geographies. Kelun-Biotech emphasizes end-to-end drug development, from molecule optimization and IND/NDA submissions to Phase 2/3 pivotal trials and partnership-driven expansion strategies. The group operates primarily in China and has pursued international collaboration and licensing arrangements to advance its ADC platform, including partnerships with multinational pharmaceutical firms and licensees to optimize global development and commercialization trajectories. Kelun-Biotech was founded in 2016 and is headquartered in Sichuan Province, China, with a corporate footprint extending to overseas markets through its HK-listed entity, reflecting a strategy of domestic strength paired with global partnering to accelerate access to innovative cancer therapies. The company maintains relationships with collaborators and subsidiaries through its parent corporate structure, with ongoing financing and strategic alliances designed to enhance its R&D pipeline, manufacturing scale, and market reach. Kelun-Biotech’s overarching objective is to deliver differentiated, clinically meaningful therapies to address unmet medical needs in oncology and immunology, supported by a robust regulatory and commercial roadmap across key regional and international markets.